Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial

CONCLUSIONS: Tivozanib demonstrated a consistent safety profile and long-term survival benefit in patients with R/R advanced RCC who were alive and progression free at 12 months. These post hoc exploratory analyses of LT-PFS and conditional OS support a clinically meaningful improvement with tivozanib versus sorafenib in this advanced RCC population.PMID:38262444 | DOI:10.1093/oncolo/oyad348

Source: The Oncologist - January 23, 2024 Category: Cancer & Oncology Authors: Kathryn E Beckermann Aviva G Asnis-Alibozek Michael B Atkins Bernard Escudier Thomas E Hutson Vijay Kasturi David F McDermott Sumanta K Pal Camillo Porta Brian I Rini Elena Verzoni Source Type: research